Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDACAMBRIDGE, Mass., Oct.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback